Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA

Vaccine

Volumn 31, Issue 41, 2013, Pages 4585-4590

  Chen, Jiang ^a   Guo, Xiao Zhong ^a   Li, Hong Yu ^a   Liu, Xu ^a   Ren, Li Nan ^a   Wang, Di ^a   Zhao, Jia Jun ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Cancer; CTL response; Dendritic cell; MUC4; Pancreatic; Survivin; Tumor associated antigen

Indexed keywords

DENDRITIC CELL VACCINE; EPITOPE; MUCIN 4; RNA; SURVIVIN; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON GAMMA RELEASE ASSAY; MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREAS CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CANCER; CTL RESPONSE; DENDRITIC CELL; MUC4; PANCREATIC; SURVIVIN; TUMOR ASSOCIATED-ANTIGEN;

CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MUCIN-4; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 84883600162     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.055     Document Type: Article

References (28)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics: 2010. CA: A Cancer Journal for Clinicians 2010, 60(5):277-300.
2. Hidalgo M. Pancreatic cancer. New England Journal of Medicine 2010, 362:1605-1617.
3. Hegmans J.P., Veltman J.D., Lambers M.E., de Vries I.J., Figdor C.G., Hendriks R.W., et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. American Journal of Respiratory and Critical Care Medicine 2010, 181(12):1383-1390.
4. Soleimani A., Berntsen A., Svane I.M., Pedersen A.E. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scandinavian Journal of Immunology 2009, 70(5):481-489.
5. Le D.T., Pardoll D.M., Jaffee E.M. Cellular vaccine approaches. Cancer Journal 2010, 16(4):304-310.
6. Fujii S., Takayama T., Asakura M., Aki K., Fujimoto K., Shimizu K. Dendritic cell-based cancer immunotherapies. Archivum Immunologiae et Therapiae Experimentalis 2009, 57(3):189-198.
7. Naka T., Iwahashi M., Nakamura M., Ojima T., Nakamori M., Ueda K., et al. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Science 2008, 99(2):407-413.
8. Moniaux N., Nollet S., Porchet N., Degand P., Laine A., Aubert J.P. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Biochemical Journal 1999, 338:325-333.
9. Shanmugam C., Jhala N.C., Katkoori V.R., Wan W., Meleth S., Grizzle W.E., et al. Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer 2010, 116(15):3577-3586.
10. Chakraborty S., Swanson B.J., Bonthu N., Batra S.K. Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. Journal of Clinical Pathology 2010, 63(7):579-584.
11. Yonezawa S., Higashi M., Yamada N., Yokoyama S., Goto M. Significance of mucin expression in pancreatobiliary neoplasm. Journal of Hepato-Biliary-Pancreatic Surgery 2010, 17(2):108-124.
12. Senapati S., Chaturvedi P., Chaney W.G., Chakraborty S., Gnanapragassam V.S., Sasson A.R., et al. Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clinical Cancer Research 2011, 17(2):267-274.
13. Carraway K.L., Theodoropoulos G., Kozloski G.A. Muc4/MUC4 functions and regulation in cancer. Future Oncology 2009, 5(10):1631-1640.
14. Miura K., Fujibuchi W., Ishida K., Naitoh T., Ogawa H., Ando T., et al. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surgery Today 2011, 41(2):175-182.
15. Liu B.B., Wang W.H. Survivin and pancreatic cancer. World Journal of Clinical Oncology 2011, 2(3):164-168.
16. Zhu H., Wang Q., Hu C., Zhang W., Quan L., Liu M., et al. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biology 2011, 32:1147-1153.
17. Miyazaki A., Kobayashi J., Torigoe T., Hirohashi Y., Yamamoto T., Yamaguchi A., et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Science 2011, 102(2):324-329.
18. Kobayashi J., Torigoe T., Hirohashi Y., Idenoue S., Miyazaki A., Yamaguchi A., et al. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. Journal of Translational Medicine 2009, 7:1.
19. Edge S.B., Compton C.C. AJCC cancer staging manual 2010, Springer, New York. 7th ed.
20. Sipos B., Möser S., Kalthoff H., Török V., Löhr M., Klöppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Archiv 2003, 442(5):444-452.
21. Chen J., Li H.-Y., Wang D., Zhao J.J., Guo X.Z. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro. Journal of Gastroenterology and Hepatology 2011, 26:1509-1518.
22. Gholamin M., Moaven O., Farshchian M., Mahmoudi M., Sankian M., Memar B., et al. Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design. BMC Cancer 2010, 7(10):261.
23. Isabelle K., Stephane V., Nicole P. MUC4 gene polymorphism and expression in women with implantation failure. Human Reproduction 2006, 21(9):2238-2245.
24. Zeis M., Siegel S., Wagner A., Schmitz M., Marget M., Kühl-Burmeister R., et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. Journal of Immunology 2003, 170(11):5391-5397.
25. Heiser A., Maurice A., Margaret, Wu N.Z., Dahm P., Pruitt S.K., et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. Journal of Immunology 2001, 166:2953-2960.
26. Michiels A., Tuyaerts S., Bonehill A., Heirman C., Corthals J., Thielemans K. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. Methods in Molecular Biology 2008, 423:155-163.
27. Van Tendeloo V.F., Ponsaerts P., Lardon F., Nijs G., Lenjou M., Van Broeckhoven C., et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001, 98(1):49-56.
28. Guo X.Z., Cui Z.M. Current diagnosis and treatment of pancreatic cancer in China. Pancreas 2005, 31:13-22.